Who is sponsoring NCT00157729?

NCT00157729 is sponsored by Medicure.

What condition does NCT00157729 study?

NCT00157729 studies Diabetes Mellitus Type 2, Hypertension, Metabolic Syndrome.

What drugs are being tested in NCT00157729?

Interventions: pyridoxal-5'-phosphate with and without ACE inhibitor.

What is the status of NCT00157729?

NCT00157729 is currently COMPLETED.

Last reviewed 2006-10-30 · How we verify

Evaluation of the Effects of MC-1 Alone and in Combination With an ACE Inhibitor on Ambulatory Blood Pressure and Metabolic Function in Hypertensive Patients With Type 2 Diabetes Mellitus

NCT00157729 Phase 2 COMPLETED

The purpose of this study is to determine whether MC-1 alone and in combination with an ACE inhibitor is effective in reducing blood pressure and metabolic dysfunctions associated with diabetes

Details

Lead sponsor	Medicure
Phase	Phase 2
Status	COMPLETED
Enrolment	160
Start date	2004-08
Completion	2005-07

Conditions

Diabetes Mellitus Type 2
Hypertension
Metabolic Syndrome

Interventions

pyridoxal-5'-phosphate with and without ACE inhibitor

Primary outcomes

Effects on blood pressure:
Determine the efficacy of MC-1 and of the combination of MC-1/ACE inhibitor on blood pressure as measured by mean daytime ambulatory systolic blood pressure.
Effects on metabolic function:
Determine the efficacy of MC-1 and of the combination of MC-1/ACE inhibitor on metabolic function as measured by insulinemia, fasting serum glucose, glycated hemoglobin, and triglycerides.

Countries

Canada